SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech - Quaterly Results

30 May 2026 Evaluate
A decrease in the sales to Rs. 3258.92 millions was observed for the quarter ended March 2026. The sales stood at Rs. 4298.84 millions during the similar quarter previous year.A big decline of -36.58% was reported for the quarter ended March 2026 to Rs. 900.22  millions from Rs. 1419.37 millions of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 1379.23 millions from 1998.07 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 3258.92 4298.84 -24.19 10550.71 12000.87 -12.08 10550.71 12000.87 -12.08
Other Income 155.42 93.84 65.62 527.31 444.47 18.64 527.31 444.47 18.64
PBIDT 1379.23 1998.07 -30.97 4292.66 5507.79 -22.06 4292.66 5507.79 -22.06
Interest 0.58 0.96 -39.58 2.34 5.29 -55.77 2.34 5.29 -55.77
PBDT 1378.65 1997.11 -30.97 4257.57 5502.50 -22.62 4257.57 5502.50 -22.62
Depreciation 194.87 146.17 33.32 743.25 543.74 36.69 743.25 543.74 36.69
PBT 1183.78 1850.94 -36.04 3514.32 4958.76 -29.13 3514.32 4958.76 -29.13
TAX 283.56 431.57 -34.30 881.65 1229.11 -28.27 881.65 1229.11 -28.27
Deferred Tax -2.93 13.42 -121.83 18.74 39.50 -52.56 18.74 39.50 -52.56
PAT 900.22 1419.37 -36.58 2632.67 3729.65 -29.41 2632.67 3729.65 -29.41
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 42.32 46.48 -8.95 40.69 45.89 -11.35 40.69 45.89 -11.35

Concord Biotech Share Price

1342.00 1.35 (0.10%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.00
Dr. Reddys Lab 1267.80
Cipla 1355.80
Zydus Lifesciences 1074.30
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: